Physician profile
Georges A Dagher
NPI 1023234242
$4,354.05
in general payments reported to CMS, 2019-2025
27 companies · $796 in 2025
The $796 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,756 · 2020: $217 · 2021: $358 · 2022: $438 · 2023: $333 · 2024: $457 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $748.80 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $626.80 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $624.91 | 2019-2025 | |
| Amgen INC. | $418.65 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $414.53 | 2019-2025 | Farxiga, Lokelma |
| Cvrx, INC. | $313.42 | 2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $274.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.70 | 2019-2025 | Jardiance |
| Abbott Laboratories | $135.81 | 2019-2022 | |
| Amarin Pharma, INC. | $106.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $83.91 | 2019-2020 | |
| Boston Scientific Corporation | $51.97 | 2019-2023 | Varithena Administration Pack |
| Abiomed | $46.30 | 2025 | |
| Novo Nordisk INC | $45.49 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $37.33 | 2025 | Onpattro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.40 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.24 | 2019 | |
| Daiichi Sankyo INC. | $21.05 | 2022 | |
| Philips North America LLC | $20.05 | 2023 | |
| Medtronic, INC. | $17.42 | 2021 | |
| Vital Connect, INC | $17.30 | 2025 | Vitalpatch Rtm |
| Irhythm Technologies, INC. | $16.69 | 2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $16.26 | 2025 | Nexletol |
| Medtronic Vascular, INC. | $13.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.04 | 2020 | |
| Chiesi USA, INC. | $10.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georges Dagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.